본문 바로가기 주메뉴 바로가기
국회도서관 홈으로 정보검색 소장정보 검색

결과 내 검색

동의어 포함

초록보기

Purpose Achieving high-quality immune reconstitution (IR) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is directly associated with the patient’s ability to resist infections, prevent tumor relapses, and suppress graft-versus-host disease (GVHD). The status of CD4 + T cells is critical for reconstituting adaptive immunity after transplantation; however, the patterns of reconstitution and their influencing factors remain unclear.

Methods This retrospective cohort study involved 164 patients who underwent myeloablative allo-HSCT from April 2016 to May 2023. Based on the early post-transplantation CD4 + T cell counts, the cohort was divided into two groups: 73 patients with high-quality IR (HIR) and 34 patients with low-quality IR (LIR). LIR was associated with an increased risk of Epstein–Barr virus (EBV) reactivation following transplantation. Plasma EBV viral load was monitored weekly using quantitative PCR for the first 100 days post-transplantation.

Results The LIR group had a higher viral load at the time of the first EBV reactivation and a significantly earlier first reactivation compared to the HIR group. No significant differences were observed in overall survival, GVHD incidence, or relapse rates between the groups. A CD4 + T cell count of < 60 cells/μL within 30 days post-transplantation was associated with a higher incidence of EBV viremia compared to the control group.

Conclusion These findings suggest that early CD4 + T cell counts may serve as a predictive marker for post-transplant EBV infection.

권호기사

권호기사 목록 테이블로 기사명, 저자명, 페이지, 원문, 기사목차 순으로 되어있습니다.
기사명 저자명 페이지 원문 목차
Molecular spectrum and carrier frequency of deletional hereditary persistence of fetal hemoglobin and delta-beta thalassemia in Malaysia Faidatul Syazlin Abdul Hamid, Sabariah Md Noor, Mei I Lai, Samsol Kamal Mohd Bahari, Ezalia Esa, Ermi Neiza Mohd Sahid, Norafiza Mohd Yasin, Yuslina Mat Yusoff p. 1-8
Novel agents and evolving strategies for anemia management in lower-risk myelodysplastic syndromes Junshik Hong p. 1-7
Treatment of transplant-ineligible multiple myeloma Jongheon Jung p. 1-7
Tandem autologous stem cell transplant in multiple myeloma patients with minimal residual disease : an explorative study Sieun Oh, Sung-Soo Park, Jung Yeon Lee, Jae-Ho Yoon, Sung-Eun Lee, Hee-Je Kim, Seung-Hwan Shin, Young-Woo Jeon, Seung-Ah Yahng, Jin Jung, Ari Ahn, Myungshin Kim, Chang-Ki Min p. 1-10
Aggressive natural killer cell leukemia therapy in the L-asparaginase era : why are we failing? Sang Eun Yoon, Junhun Cho, Hyun-Young Kim, Seok Jin Kim, Won Seog Kim p. 1-13
Unveiling the role of microRNAs, the PI3K/AKT pathway, and their associations in various types of leukemia : a comprehensive review Amir Modarresi Chahardehi, Esfandiar Mali, Arya Afrooghe, Amirmasoud Asadi, Amirreza Khalaji, Hamed Soleimani Samarkhazan, Hananeh Esmaeil Beygi, Amirhossein Mohagheghi, Maryam Khanbabaei, Heliya Haghani, Reza Arefnezhad, Fatemeh RezaeiTazangi p. 1-13
Early CD4 + T cell immune reconstitution as a biomarker for Epstein-Barr virus control following allogeneic transplantation Kexin Lin, Wenwen Yang, Jiaxiu Yin, Jing Luo, Hao Zhou, Lanxiang Liu, Li Yang, Jie Luo, Lin Liu, Junli Mou p. 1-10
Beyond anemia : unraveling neutrophil defects and infection susceptibility in β-Thalassemia Chingiz Asadov, Gunay Aliyeva p. 1-10
(Correspondence) Durable responses and favorable cost-effectiveness of rituximab‑based chemoimmunotherapy for primary cold agglutinin disease Kenichi Ito, Tomoko Kitagawa, Saya Motohashi, Kazuhiko Hirano, Naohiro Sekiguchi p. 1-6
(Correspondence) Current immunotherapeutic approaches for relapsed/refractory follicular lymphoma : bispecific antibodies and CAR T-Cell therapies So Yeon Park, Gi-June Min p. 1-6
(A) comparative study of hematologic response to ropeginterferon alfa-2b in hydroxyurea-resistant or intolerant polycythemia vera : a real-world data-based analysis Sung-Eun Lee, Seug Yun Yoon, Sung-Yong Kim, Soo-Mee Bang, Insoo Lee, Jihyuk Lee, Junshik Hong p. 1-7
Plasma interleukin : 12 levels as a potential biomarker of fatigue and quality of life in patients with primary immune thrombocytopenia Wadhera Sarthak, Jain Arihant, Sahni Aarushi, Swain Rudra Narayan, Singh Charanpreet, Jandial Aditya, Aggarwal Ritu, Hans Rekha, Prakash Gaurav, Khadwal Alka, Grover Sandeep, Das Reena, Malhotra Pankaj p. 63-63
Brentuximab vedotin combined with cisplatin, cytarabine, and dexamethasone treatment in transplant : eligible Korean patients with relapsed or refractory Hodgkin’s lymphoma Yi Jun Ho, Park Young Hoon, Lee Myung-won, Yoo Kwai Han, Hong Junshik, Eom Hyeon-Seok p. 62-62
Insights into Treatment : Free Remission (TFR) outcomes in Chronic Myeloid Leukaemia (CML) – a tertiary centre experience in Malaysia Liam Christopher Chin Keong, Boo Yang Liang, Lim Li Min, Chong Siew Lian, Sharif Azizan, Wong Yih Seong, Selvaratnam Veena, Tan Sen Mui, Lim Soo Min p. 64-64
Invasive fungal infections in hematologic diseases : evidence, challenges, and clinical practice Cho Sung-Yeon, Lee Chae Eun, Nho Dukhee, Lee Dong-Gun p. 65-65
Measurable residual disease monitoring after hematopoietic stem cell transplantation Shin Saeam p. 66-66
Translational investigation of tolinapant (ASTX660) in acute myeloid leukemia by integrating clinical, bioinformatic and pharmacological approaches Lima Keli, Nogueira Frederico Lisboa, Reis-Silva Catarina Sofia Mateus, de Cássia Cavaglieri Rita, Costa-Lotufo Leticia Veras, Machado-Neto João Agostinho, Rego Eduardo Magalhães p. 67-67